Download PDF
Phlebologie 2015; 44(01): 7-13
DOI: 10.12687/phleb2233-1-2015
Original article
Schattauer GmbH

Treatment of high risk pregnancies

Article in several languages: English | deutsch
H Kiesewetter
1   MVZ Hämostaseologicum; Berlin/Germany
,
R Becker
2   Private practice in Berlin, Germany
,
M Breitkopf
2   Private practice in Berlin, Germany
,
S Baumgarten
2   Private practice in Berlin, Germany
,
G Halis
2   Private practice in Berlin, Germany
,
A Höhne
2   Private practice in Berlin, Germany
,
A Jantke
2   Private practice in Berlin, Germany
,
C Kießling-Rau
2   Private practice in Berlin, Germany
,
K Kuhlmann
2   Private practice in Berlin, Germany
,
S Kunert
2   Private practice in Berlin, Germany
,
M Entezami
2   Private practice in Berlin, Germany
,
DJ Peet
2   Private practice in Berlin, Germany
,
M Reißig
2   Private practice in Berlin, Germany
,
B Ristau
2   Private practice in Berlin, Germany
,
FP Schmidt
2   Private practice in Berlin, Germany
,
P Sydow
2   Private practice in Berlin, Germany
,
P Tabor-Wessel
2   Private practice in Berlin, Germany
,
E Yüksel
2   Private practice in Berlin, Germany
,
R Duncker
4   Private practice in Trebbin, Germany
,
R Münchow
5   Private practice in Werder, Germany
,
A Röding
6   Private practice in Nauen, Germany
,
S Clausnitzer
3   Private practice in Potsdam, Germany
,
FH Giers
3   Private practice in Potsdam, Germany
,
M Hubatsch
3   Private practice in Potsdam, Germany
,
S Maas
3   Private practice in Potsdam, Germany
,
K-T Moeller
3   Private practice in Potsdam, Germany
,
A Stellmacher
3   Private practice in Potsdam, Germany
,
M Zöllner
3   Private practice in Potsdam, Germany
› Author Affiliations
Further Information

Publication History

Received: 03 September 2014

Accepted after major revision: 10 December 2014

Publication Date:
04 January 2018 (online)

    Permissions and Reprints

Summary

Introduction: The efficacy of a therapy with certoparin; also in combination with aspirin and prednisolone; in high-risk pregnancies has been examined prospectively.

Method: Data of 616 pregnancies have been analyzed. 238 patients injected Mono Embolex 3000; 239 patients Mono Embolex 8000 only. 62 patients injected Mono Embolex 8000 and took aspirin 50–100 mg daily; 60 Mono Embolex 3000 and aspirin 50–100 mg daily. 30 patients took aspirin 50–100 mg; prednisolone 2.5–5 mg and 17 injected mono Embolex 8000; 13 Mono Embolex 3000 daily from the start of their pregnancy. The target variable was the life birth rate.

When given aspirin the HPA-status of the partner is measured if the pregnant woman is negative for HPA 1a or 5b. In HPA-negative mothers and HPA-positive fathers a test for HPA-antibodies is performed posterior week 16.

Result: Applied early; a mean life birth rate of 95 % has been achieved in the monotherapy with Mono Embolex. Where heparin and aspirin were applied before pregnancy week 17 a life birth rate of 100 % was achieved. In patientswith a combination of aspirin and prednisolone a life birth rate of 87 % was achieved. Considering the life birth rate the status of thrombophilia gene-polymorphisms is irrelevant. The HPA-status was examined in 139 patients. In one of the HPA 5a-negative and 3 of the HPA 5b-negative women an immunization occurred but the platelet count of the fetus was not decreased. 3.3 % showed local allergic reaction and 0.5 % slight bleeding.

Conclusion: Certoparin, aspirin and prednisolone are safe drugs to increase life birth rate.

Keywords

Risk pregnancies - heparin - aspirin - predniso-lone - life birth rate
 

  • References

  • 1 Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften – 015/018: Hypertensive Schwangerschaftserkrankungen: Diagnostik und Therapie 12/2013
  • 2 Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften – 015/050: Diagnostik und Therapie beim wiederholten Spontanabort: 12/2013
  • 3 Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften – 003/001: S3-Leitlinie Prophylaxe der Venösen Thromboembolie (VTE) 06/2010
  • 4 Askie LM, Duley L, Henderson-Smart DJ, Stewart LA. PARIS Collaborative Group.. Antiplatelet agents for prevention of pre-eclampsia: a metaanalysis of individual patient data. Lancet 2007; 369 9575 1791-1798.
    CrossrefPubMedGoogle Scholar
  • 5 Bakchoul T, Bassler D, Heckmann M, Thiele T, Kiefel V, Gross I, Arnold DM, DiTomasso J, Smith JW, Paes B, Greinacher A. Management of infants born with severe neonatal alloimmune thrombocytopenia: the role of platelet transfusions and intravenous immunoglobulin. Transfusion 2014; 54 (Suppl. 03) 640-645.
    CrossrefPubMedGoogle Scholar
  • 6 Bassler D, Greinacher A, Okascharoen C, Klenner A, Ditomasso J, Kiefel V, Chan A, Paes B. A systematic review and survey of the management of unexpected neonatal alloimmune thrombocytopenia. Transfusion 2008; 48 (Suppl. 01) 92-98.
    PubMedGoogle Scholar
  • 7 Bauersachs RM, Dudenhausen J, Faridi A, Fischer T, Fung S, Geisen U, Harenberg J, Herchenhan E, Keller F, Kemkes-Matthes B, Schinzel H, Spannagl M, Thaler CJ. EThIG Investigators.. Risk stratification and heparin prophylaxis to prevent venous thromboembolism in pregnant women. Thromb Haemost 2007; 98 (Suppl. 06) 1237-1245.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Becker R, Keller T, Kiesewetter H, Fangerau H, Bittner U. Individual risk assessment of adverse pregnancy outcome by multivariate regression analysis may serve as basis for drug intervention studies: retrospective analysis of 426 high-risk patients including ethical aspects. Arch Gynecol Obstet 2013; 288 (Suppl. 01) 41-48.
    CrossrefPubMedGoogle Scholar
  • 9 Bujold E, Roberge S, Lacasse Y, Bureau M, Audi-bert F, Marcoux S, Forest JC, Giguère Y. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 2010; 116 2 Pt 1 402-414.
    CrossrefPubMedGoogle Scholar
  • 10 Carp H, Dolitzky M, Inbal A. Thromboprophylaxis improves the live birth rate in women with consecutive recurrent miscarriages and hereditary thrombophilia. J Thromb Haemost 2003; 1 (Suppl. 03) 433-438.
    CrossrefPubMedGoogle Scholar
  • 11 Clark P, Walker ID, Langhorne P, Crichton L, Thomson A, Greaves M, Whyte S, Greer IA. Scottish Pregnancy Intervention Study (SPIN) collaborators.. SPIN (Scottish Pregnancy Intervention) study: a multicenter, randomized controlled trial of low-molecular-weight heparin and low-dose aspirin in women with recurrent miscarriage. Blood 2010; 115 (Suppl. 21) 4162-4167.
    CrossrefPubMedGoogle Scholar
  • 12 CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women.. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. Lancet 1994; 12 343 8898 619-629.
    Google Scholar
  • 13 Coomarasamy A, Papaioannou S, Gee H, Khan KS. Aspirin for the prevention of preeclampsia in women with abnormal uterine artery Doppler: a meta-analysis. Obstet Gynecol 2001; 98 5 Pt 1 861-866.
    PubMedGoogle Scholar
  • 14 Di Nisio M, Peters L, Middeldorp S. Anticoagulants for the treatment of recurrent pregnancy loss in women without antiphospholipid syndrome. Cochrane Database Syst Rev 2005; 2: CD004734.
    Google Scholar
  • 15 Dolitzky M, Inbal A, Segal Y, Weiss A, Brenner B, Carp H. A randomized study of thromboprophylaxis in women with unexplained consecutive recurrent miscarriages. Fertil Steril 2006; 86 (Suppl. 02) 362-366.
    CrossrefPubMedGoogle Scholar
  • 16 Dodd JM, McLeod A, Windrim RC, Kingdom J. Antithrombotic therapy for improving maternal or infant health outcomes in women considered at risk of placental dysfunction. Cochrane Database Syst Rev 2013; 7.
    Google Scholar
  • 17 Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2007; 2: CD004659.
    Google Scholar
  • 18 Fachinformation ASS 08/2011
  • 19 Fachinformation Prednisolon 05/2014
  • 20 Fawzy M, El-Refaeey AA. Does combined prednisolone and low molecular weight heparin have a role in unexplained implantation failure?. Arch Gynecol Obstet 2014; 289 (Suppl. 03) 677-680.
    CrossrefPubMedGoogle Scholar
  • 21 Franklin RD, Kutteh WH. Antiphospholipid antibodies (APA) and recurrent pregnancy loss: treating a unique APA positive population. Hum Reprod 2002; 17 (Suppl. 11) 2981-2985.
    CrossrefPubMedGoogle Scholar
  • 22 Hanke AA, Roberg K, Monaca E, Sellmann T, Weber CF, Rahe-Meyer N, Görlinger K. Impact of platelet count on results obtained from multiple electrode platelet aggregometry (Multiplate). Eur J Med Res 2010; 15 (Suppl. 05) 214-219.
    CrossrefPubMedGoogle Scholar
  • 23 Gomaa MF, Elkholy AG, El-Said MM, AbdelSalam NE. Combined oral prednisolone and heparin versus heparin: the effect on peripheral NK cells and clinical outcome in patients with unexplained recurrent miscarriage. A double-blind placebo randomized controlled trial. Arch Gynecol Obstet 2014; 290 (Suppl. 04) 757-762.
    CrossrefPubMedGoogle Scholar
  • 24 Gris JC, Mercier E, Quéré I, Lavigne-Lissalde G, Cochery-Nouvellon E, Hoffet M, Ripart-Neveu S, Tailland ML, Dauzat M, Marès P. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood 2004; 103 (Suppl. 10) 3695-3699.
    CrossrefPubMedGoogle Scholar
  • 25 Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton 3rd LJ. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med 2005; 143 (Suppl. 10) 697-706.
    CrossrefPubMedGoogle Scholar
  • 26 Henderson JT, Whitlock EP, O’Connor E, Senger CA, Thompson JH, Rowland MG. Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 2014; 160 (Suppl. 10) 695-703.
    CrossrefPubMedGoogle Scholar
  • 27 Jäger M. Das Hirnblutungsrisiko bei Neugeborenen. Dissertation an der Justus-Liebig-Universität Gießen 2001
    PubMedGoogle Scholar
  • 28 Janson A, Alm J, Bremme K, Skjöldebrand-Sparre L, Söder O, Werner S. [Cooperation reduces the risks of thyroid disease in pregnancy. Also mild maternal hypothyroidism can threaten the neurological development of the fetus]. Lakartidningen 2002; 99 (Suppl. 09) 899-903.
    PubMedGoogle Scholar
  • 29 Kaandorp SP, Goddijn M, van der Post JA, Hutten BA, Verhoeve HR, Hamulyák K, Mol BW, Folkeringa N, Nahuis M, Papatsonis DN, Büller HR, van der Veen F, Middeldorp S. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med 2010; 362 (Suppl. 17) 1586-1596.
    CrossrefPubMedGoogle Scholar
  • 30 Kiesewetter H, Radtke H, Becker R, Schmidt FP, Körber K, Vehlow N. [Risk pregnancies and how to treat them]. Hamostaseologie 2012; 32 01 S90-94.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Kiesewetter H, Radtke H, Schmidt FP, Körber K. Venöse Thromboembolie – Tumor als Risikofaktor. Praktische Dermatologie 2013; 340-346.
    Google Scholar
  • 32 Kjeldsen-Kragh J, Husebekk A, Killie MK, Skogen B. Is it time to include screening for neonatal alloimmune thrombocytopenia in the general ante-natal health care programme?. Transfus Apher Sci 2008; 38 (Suppl. 03) 183-188.
    CrossrefPubMedGoogle Scholar
  • 33 Knudsen UB, Hansen V, Juul S, Secher NJ. Prognosis of a new pregnancy following previous spontaneous abortions. Eur J Obstet Gynecol Reprod Biol 1991; 39 (Suppl. 01) 31-36.
    CrossrefPubMedGoogle Scholar
  • 34 Körber K, Kiesewetter H, Radtke H, Schmidt FP, Becker R, Maas S, Ristau B, Baumgarten S, Pruß A. Therapeutischer Nutzen von niedermolekularem Heparin bei Frauen mit rezidivierenden Aborten. Phlebologie 2012; 41: 129-134.
    Article in Thieme ConnectGoogle Scholar
  • 35 Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996; 174 (Suppl. 05) 1584-1589.
    CrossrefPubMedGoogle Scholar
  • 36 Laskin CA, Spitzer KA, Clark CA, Crowther MR, Ginsberg JS, Hawker GA, Kingdom JC, Barrett J, Gent M. Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial. J Rheumatol 2009; 36 (Suppl. 02) 279-287.
    CrossrefPubMedGoogle Scholar
  • 37 Mak A, Cheung MW, Cheak AA, Ho RC. Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression. Rheumatology 2010; 49 (Suppl. 02) 281-288.
    CrossrefPubMedGoogle Scholar
  • 38 Mello G, Parretti E, Fatini C, Riviello C, Gensini F, Marchionni M, Scarselli GF, Gensini GF, Abbate R. Low-molecular-weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensin-converting enzyme DD women. Hypertension 2005; 45 (Suppl. 01) 86-91.
    CrossrefPubMedGoogle Scholar
  • 39 Qublan H, Amarin Z, Dabbas M, Farraj AE, BeniMerei Z, Al-Akash H, Bdoor AN, Nawasreh M, Malkawi S, Diab F, Al-Ahmad N, Balawneh M, Abu-Salim A. Low-molecular-weight heparin in the treatment of recurrent IVF-ET failure and thrombophilia: a prospective randomized placebo-controlled trial. Hum Fertil (Camb) 2008; 11 (Suppl. 04) 246-253.
    CrossrefPubMedGoogle Scholar
  • 40 Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or anti-phospholipid antibodies). BMJ 1997; 314 7076 253-257.
    CrossrefPubMedGoogle Scholar
  • 41 Red-Horse K, Zhou Y, Genbacev O, Prakobphol A, Foulk R, McMaster M, Fisher SJ. Trophoblast differentiation during embryo implantation and formation of the maternal-fetal interface. J Clin Invest 2004; 114 (Suppl. 06) 744-754.
    CrossrefPubMedGoogle Scholar
  • 42 Regan L, Braude PR, Trembath PL. Influence of past reproductive performance on risk of spontaneous abortion. BMJ 1989; 299 6698 541-545.
    CrossrefPubMedGoogle Scholar
  • 43 Reinhard G, Noll A, Schlebusch H, Mallmann P, Ruecker AV. Shifts in the TH1/TH2 balance during human pregnancy correlate with apoptotic changes. Biochem Biophys Res Commun 1998; 245 (Suppl. 03) 933-938.
    CrossrefPubMedGoogle Scholar
  • 44 Remer T, Manz F. Potential renal acid load of foods and its influence on urine pH. J Am Diet Assoc 1995; 95 (Suppl. 07) 791-797.
    CrossrefPubMedGoogle Scholar
  • 45 Rey E, Garneau P, David M, Gauthier R, Leduc L, Michon N, Morin F, Demers C, Kahn SR, Magee LA, Rodger M. Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. J Thromb Haemost 2009; 7 (Suppl. 01) 58-64.
    CrossrefPubMedGoogle Scholar
  • 46 Rey E, Rivard GE. Is testing for aspirin response worthwhile in high-risk pregnancy?. Eur J Obstet Gynecol Reprod Biol 2011; 157 (Suppl. 01) 38-42.
    CrossrefPubMedGoogle Scholar
  • 47 Roberge S, Giguère Y, Villa P, Nicolaides K, Vainio M, Forest J-C, von Dadelzen P, Vaiman D, Tapp S, Bujold E. Early Administration of Low-Dose Aspirin for the Prevention of Severe and Mild Preeclampsia: A Systematic Review and Meta-Analysis. Amer J Perinatol 2012; 29 (Suppl. 07) 551-556.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 48 Robertson L, Wu O, Langhorne P, Twaddle S, Clark P, Lowe GDO, Walker ID, Greaves M, Brenkel I, Regan L, and Greer IA. for The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study.. Thrombophilia in pregnancy: a systematic review. British Journal of Haematology 2006; 132: 171-196.
    CrossrefPubMedGoogle Scholar
  • 49 Ruano R, Fontes RS, Zugaib M. Prevention of preeclampsia with low-dose aspirin -- a systematic review and meta-analysis of the main randomized controlled trials. Clinics 2005; 60 (Suppl. 05) 407-414.
    CrossrefPubMedGoogle Scholar
  • 50 Schleussner E, Kamin G, Seeliger G, Rogenhofer N, Bauersachs R. ETHIG Studiengruppe.. Niedermolekulares Heparin ohne Effekt bei unerklärter habitueller Abortneigung. Z Geburtshilfe Neonatol 2013; 217: V26_2.
    Article in Thieme ConnectGoogle Scholar
  • 51 Stirrat GM. Recurrent miscarriage. Lancet 1990; 336 8716 673-675.
    CrossrefPubMedGoogle Scholar
  • 52 Subtil D, Goeusse P, Puech F, Lequien P, Biausque S, Breart G, Uzan S, Marquis P, Parmentier D, Churlet A. Essai Régional Aspirine Mère-Enfant (ERASME) Collaborative Group.. Aspirin (100 mg) used for prevention of pre-eclampsia in nulliparous women: the Essai Régional Aspirine Mère-Enfant study (Part 1). BJOG 2003; 110 (Suppl. 05) 475-484.
    PubMedGoogle Scholar
  • 53 Subtil D, Goeusse P, Houfflin-Debarge V, Puech F, Lequien P, Breart G, Uzan S, Quandalle F, Delcourt YM, Malek YM. Essai Régional Aspirine Mère-Enfant (ERASME) Collaborative Group.. Randomised comparison of uterine artery Doppler and aspirin (100 mg) with placebo in nulliparous women: the Essai Régional Aspirine Mère-Enfant study (Part 2). BJOG 2003; 110 (Suppl. 05) 485-491.
    CrossrefPubMedGoogle Scholar
  • 54 Trivedi NA. A meta-analysis of low-dose aspirin for prevention of preeclampsia. J Postgrad Med 2011; 57 (Suppl. 02) 91-95.
    CrossrefPubMedGoogle Scholar
  • 55 WHO-World Health-Organisation.. Global causes of maternal death 2014; e323-e333.